Features  |   May 2017
Mivacurium: Return of a Drug Seeking an Indication?
Author Affiliations
  • Roy G. Soto, M.D.
    Committee on Patient Safety and Education
  • David Dunipace, CAA, M.S.
    Committee on Patient Safety and Education
Article Information
Neuromuscular Diseases and Drugs / Features
Features   |   May 2017
Mivacurium: Return of a Drug Seeking an Indication?
ASA Monitor 05 2017, Vol.81, 30-31.
ASA Monitor 05 2017, Vol.81, 30-31.
Mivacurium is a benzylisoquinolinium nondepolarizing neuromuscular-blocking drug that was developed in the early 1980s and disappeared from the U.S. market in 2006. It was reintroduced in December 2016, and many have asked what the appropriate niche is for this seemingly resurrected medication.
Since the successful introduction of succinylcholine in the mid-20th century, there have been many attempts to duplicate its quick onset and short duration of action without the negative effects of depolarizing paralytics. Mivacurium has an onset time similar to most other intermediate-acting neuromuscular blocking agents (NMBAs), but a shorter duration of action. While it was available, many used the drug for short cases or for cases when reversal was not wanted. Others avoided the drug due to untoward side effects, notably histamine release.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×